Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-08-08
2006-08-08
Jones, Dwayne (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252140, C514S269000, C514S272000
Reexamination Certificate
active
07087608
ABSTRACT:
The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrim-idine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R1is pyridyl bonded at a carbon atom, R2, R3, R5, R6and R8are each hydrogen, R4is lower alkyl, R7a radical of formula (II): —N(R9)—C(═X)—(Y)n—R10, wherein R9hydrogen, X is oxo, n is 0 and R10is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.
REFERENCES:
patent: 5093330 (1992-03-01), Caravatti et al.
patent: 0 564 409 (1993-10-01), None
patent: 0 622 077 (1994-11-01), None
patent: 0 826 686 (1998-03-01), None
patent: 96 13259 (1996-05-01), None
patent: 96 33179 (1996-10-01), None
patent: 98 35958 (1998-08-01), None
patent: 99 03854 (1999-01-01), None
patent: 99 58128 (1999-11-01), None
patent: 00 09098 (2000-02-01), None
Baran, Dana et al., “The new tyrosine kinase inhibitor CGP 53716 specifically inhibits PDGF-driven murine mesangial cell (MC) proliferation,” Journal of the American Society of Nephrology, vol. 9, No. Program and Abstr. Issue, pp. 433A (1997).
Bird, Eileen et al., “Effects of a platelet-derived growth factor (PDGF) receptor kinase inhibitor, RPR-101511a, in acute glomerulonephritis in rats,” Journal of the American Society of Nephrology, vol. 10, p. 568A (1999).
Woo K. T., “Recent concepts in the pathogenesis and therapy of IgA nephritis,” Annals Academy of Medicine Singapore, vol. 25(2), pp. 265-269 (1996).
Gilbert, Richard E. et al., “PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis,” Kidney International, vol. 59(4), pp. 1324-1332 (2001).
Sugimoto, Yukio et al., “Preparation of N-(hetero)aryl-p-aminophenol derivatives for elimination of active oxygen species,” Database Chemabs Online, Chemical Abstracts, Database Accession No. 116:41485.
Chadban et al., “Defective B Cell CD22 Expression by Lupus Prone NZBWF1 Mice,” Abstract, Australia and New Zealand Society of Nephrology, Ann. Scientific Meeting, Melbourne, end of Mar. 2000.
Nakamura et al., “mRNA Expression of Growth Factors in Glomeruli from Diabetic Rats,” Diabetes, vol. 42, pp. 450-456 (1999).
Throckmorton et al., “PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products,” Kidney International, vol. 48, pp. 111-117 (1995).
Doi et al., “Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor,” Proc. Natl. Acad. Sci. USA, vol. 89, pp. 2873-2877 (1992).
Hulthen et al., “Vascular Hypertrophy and Albumin Permeability in a Rat Model Combining Hypertension and Diabetes Mellitus,” American Journal of Hypertension Ltd., pp. 895-901 (1996).
Cao et al., “Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action,” Journal of Hypertension, vol. 16, 793-799 (1998).
Allen et al., “Role of Angiotensin II and Bradykinin in Experimental Diabetic Nephropathy,” Diabetes, vol. 46, pp. 1612-1618 (1997).
Buchdunger et al., “Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class,” Proc. Natl. Acad. Sci., vol. 92, pp. 2558-2562 (1995).
Major et al., “Inhibition of Cell Growth: Effects of the Tyrosine Kinase Inhibitor CGP 53716,” The Journal of Pharmacology and Eperimental Therapeutics, vol. 283(1), pp. 402-410 (1997).
Remuzzi et al., “Prevention of Renal Injury in Diabetic MWF Rats by Angiotensin II Antagonism,” Exp Nephrology, vol. 6, pp. 28-38 (1998).
Woo K. T., “Recent concepts in the pathogenesis and therapy of IgA nephritis,” Annals Academy of Medicine Singapore, vol. 25(2), pp. 265-269 (1996).
Gilbert, Richard E. et al., “PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis,” Kidney International, vol. 59(4), pp. 1324-1332 (2001).
Sugimoto, Yukio et al., “Preparation of N-(hetero)aryl-p-aminophenol derivatives for elimination of active oxygen species,” Database Chemabs Online, Chemical Abstracts, Database Accession No. 116:41485, 1991.
Atkins Robert Charles
Chadban Steven James
Cooper Mark Emmanuel
Gilbert Richard Ernest
Hill Prudence Ann
Dohmann George R.
Jackson Oona A.
Jones Dwayne
LandOfFree
Use of PDGF receptor tyrosine kinase inhibitors for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of PDGF receptor tyrosine kinase inhibitors for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of PDGF receptor tyrosine kinase inhibitors for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3714974